Skip to content

Study · Case report or series · n = 1 · 1988

7 results

Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.

Sassolas G, Lejeune H, Trouillas J, Forest MG, Claustrat B, Lahlou N, Loras B

The Journal of clinical endocrinology and metabolism1 Jul 1988Cited by 26 (Europe PMC)

PMID2967850 (opens in a new tab)DOI10.1210/jcem-67-1-180 (opens in a new tab)PepBankPUB-02967850
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In the triptorelin-treated patient, plasma FSH increased initially and remained above pretreatment values.

    In plain wordsIn the triptorelin-treated patient, FSH increased and remained above pretreatment levels.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreasePlasma FSH
    Study

    n = 1

    Recurrent gonadotropin-secreting pituitary adenoma
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg every 21 days, three injectionsAs given in this study (human).

    Source sentences

    Summary
    In both patients, plasma FSH, LH (RIA), and alpha-subunit concentrations increased initially and remained above the pretreatment values throughout the treatment period.
    2 context sentences
    Summary · context
    We studied the effect of GnRH analog treatment in two such patients, one with a recurrent FSH- and LH-secreting pituitary adenoma (patient 1) and one with a recurrent FSH- and alpha-subunit-secreting pituitary adenoma (patient 2).
    Summary · context
    Patient 1 was treated with 200 micrograms Buserelin daily for 65 days, and patient 2 received three injections of 3 mg [D-Trp6]-LHRH formulated in microcapsules at 21-day intervals.
  2. 02HumanCase report or seriesEfficacy outcome

    In the triptorelin-treated patient, plasma LH measured by RIA increased and remained above pretreatment values.

    In plain wordsIn the triptorelin-treated patient, LH measured by RIA increased and remained above pretreatment levels.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreasePlasma LH by RIA
    Study

    n = 1

    Recurrent gonadotropin-secreting pituitary adenoma
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg every 21 days, three injectionsAs given in this study (human).

    Source sentences

    Summary
    In both patients, plasma FSH, LH (RIA), and alpha-subunit concentrations increased initially and remained above the pretreatment values throughout the treatment period.
    2 context sentences
    Summary · context
    We studied the effect of GnRH analog treatment in two such patients, one with a recurrent FSH- and LH-secreting pituitary adenoma (patient 1) and one with a recurrent FSH- and alpha-subunit-secreting pituitary adenoma (patient 2).
    Summary · context
    Patient 1 was treated with 200 micrograms Buserelin daily for 65 days, and patient 2 received three injections of 3 mg [D-Trp6]-LHRH formulated in microcapsules at 21-day intervals.
  3. 03HumanCase report or seriesEfficacy outcome

    In the triptorelin-treated patient, plasma alpha-subunit increased and remained above pretreatment values.

    In plain wordsIn the triptorelin-treated patient, alpha-subunit levels increased and remained above pretreatment levels.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreasePlasma alpha-subunit
    Study

    n = 1

    Recurrent gonadotropin-secreting pituitary adenoma
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg every 21 days, three injectionsAs given in this study (human).

    Source sentences

    Summary
    In both patients, plasma FSH, LH (RIA), and alpha-subunit concentrations increased initially and remained above the pretreatment values throughout the treatment period.
    2 context sentences
    Summary · context
    We studied the effect of GnRH analog treatment in two such patients, one with a recurrent FSH- and LH-secreting pituitary adenoma (patient 1) and one with a recurrent FSH- and alpha-subunit-secreting pituitary adenoma (patient 2).
    Summary · context
    Patient 1 was treated with 200 micrograms Buserelin daily for 65 days, and patient 2 received three injections of 3 mg [D-Trp6]-LHRH formulated in microcapsules at 21-day intervals.
  4. 04HumanCase report or seriesActivity measurement

    In the triptorelin-treated patient, LH measured by immunoradiometric assay remained well above the detection limit.

    In plain wordsIn the triptorelin-treated patient, one LH test remained well above its detection limit.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableLH by immunoradiometric assay
    Study

    n = 1

    Recurrent gonadotropin-secreting pituitary adenoma
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg every 21 days, three injectionsAs given in this study (human).

    Source sentences

    Summary
    Plasma LH, measured by immunoradiometric assay, remained well above the detection limit.
    2 context sentences
    Summary · context
    We studied the effect of GnRH analog treatment in two such patients, one with a recurrent FSH- and LH-secreting pituitary adenoma (patient 1) and one with a recurrent FSH- and alpha-subunit-secreting pituitary adenoma (patient 2).
    Summary · context
    Patient 1 was treated with 200 micrograms Buserelin daily for 65 days, and patient 2 received three injections of 3 mg [D-Trp6]-LHRH formulated in microcapsules at 21-day intervals.
  5. 05HumanCase report or seriesEfficacy outcome

    In patient 2, bioactive LH became undetectable during triptorelin treatment.

    In plain wordsIn patient 2, bioactive LH became undetectable during triptorelin treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseBioactive LH
    Study

    n = 1

    Recurrent gonadotropin-secreting pituitary adenoma
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg every 21 days, three injectionsAs given in this study (human).

    Source sentences

    Summary
    Plasma bioactive LH and testosterone became undetectable in patient 2, but did not change in patient 1.
    2 context sentences
    Summary · context
    We studied the effect of GnRH analog treatment in two such patients, one with a recurrent FSH- and LH-secreting pituitary adenoma (patient 1) and one with a recurrent FSH- and alpha-subunit-secreting pituitary adenoma (patient 2).
    Summary · context
    Patient 1 was treated with 200 micrograms Buserelin daily for 65 days, and patient 2 received three injections of 3 mg [D-Trp6]-LHRH formulated in microcapsules at 21-day intervals.
  6. 06HumanCase report or seriesEfficacy outcome

    In patient 2, testosterone became undetectable during triptorelin treatment.

    In plain wordsIn patient 2, testosterone became undetectable during triptorelin treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseTestosterone
    Study

    n = 1

    Recurrent gonadotropin-secreting pituitary adenoma
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg every 21 days, three injectionsAs given in this study (human).

    Source sentences

    Summary
    Plasma bioactive LH and testosterone became undetectable in patient 2, but did not change in patient 1.
    2 context sentences
    Summary · context
    We studied the effect of GnRH analog treatment in two such patients, one with a recurrent FSH- and LH-secreting pituitary adenoma (patient 1) and one with a recurrent FSH- and alpha-subunit-secreting pituitary adenoma (patient 2).
    Summary · context
    Patient 1 was treated with 200 micrograms Buserelin daily for 65 days, and patient 2 received three injections of 3 mg [D-Trp6]-LHRH formulated in microcapsules at 21-day intervals.
  7. 07HumanCase report or seriesEfficacy outcome

    In the triptorelin-treated patient, pituitary tumor size did not change during treatment.

    In plain wordsIn the triptorelin-treated patient, pituitary tumor size did not change.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePituitary tumor size
    Study

    n = 1

    Recurrent gonadotropin-secreting pituitary adenoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3 mg every 21 days, three injectionsAs given in this study (human).

    Source sentences

    Summary
    In neither patient did pituitary tumor size (determined by computed tomographic scan) change during treatment.
    2 context sentences
    Summary · context
    We studied the effect of GnRH analog treatment in two such patients, one with a recurrent FSH- and LH-secreting pituitary adenoma (patient 1) and one with a recurrent FSH- and alpha-subunit-secreting pituitary adenoma (patient 2).
    Summary · context
    Patient 1 was treated with 200 micrograms Buserelin daily for 65 days, and patient 2 received three injections of 3 mg [D-Trp6]-LHRH formulated in microcapsules at 21-day intervals.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.